Skip to content

Assessment the efficacy of atomoxetin(stramox) in autism spectrum disorders

Assessment the efficacy of atomoxetin(stramox) in autism spectrum disorders 6-17 years old

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016022826802N1
Enrollment
40
Registered
2016-08-31
Start date
2015-08-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism spectrum disorders. Childhood autism

Interventions

Intervention 1: The intervention group have been treated with risperidone is also treated with atomoxetine. Dosing and titration of the drug individually, but the total dose of atomoxetine is 0.5 mg
Treatment - Drugs
The intervention group have been treated with risperidone is also treated with atomoxetine. Dosing and titration of the drug individually, but the total dose of atomoxetine is 0.5 mg per kg at the st
The intervention group have been treated with risperidone is also treated with placebo. The duration of intervention is 8 weeks.

Sponsors

Vice chancellor for research of mashhad university of medical sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 17 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria: Of all patients with ASD, ranging in age from 6 to 17 years; Parent's Consent; No obvious organic disease; The lack of other psychiatric disorders; Not taking other psychoactive medications other than risperidone; IQ higher than 50 on the basis of Weiland test The exclusion criteria: In the absence of cooperation of parents after inclusion; the risk of any side effect or another disease that cause a problem in results.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Autism. Timepoint: Previous the syudy, 4 weeks after study, 8 weeks after study. Method of measurement: CARS test,CGI test.

Secondary

MeasureTime frame
Drug's side effect. Timepoint: Previous the study, 4weeks after study, 8 weeks after study. Method of measurement: Check list.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mahbubeh Eslamzadeh

Mashhad University of Medical sciences

eslamzadehm921@mums.ac.ir+98 51 3711 2721

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 24, 2026